Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

- PMLiVE

Austrian State Secretary to speak at FlyPharma Europe 2023

Register now to get industry insights from a host of expert industry speakers

- PMLiVE

Further data for AstraZeneca/Daichii Sankyo’s Enhertu requested by NICE

Enhertu is currently approved for HER2-low metastatic breast cancer in over 30 countries

- PMLiVE

EDX Medical Group develops multi-disease ‘point-of-care’ rapid tests for cancer, infections and cardiovascular conditions

The development follows the Group’s acquisition of Hutano Diagnostics

- PMLiVE

Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate

The US company will initiate a phase 2 study to evaluate the vaccine candidate

- PMLiVE

ScreenPoint Medical to showcase AI software at European scientific meeting

Trial results show that the software boosts breast cancer detection by 20%

- PMLiVE

Presenting Outstanding Outcomes from HCP Education in Multiple Myeloma at IMS in Athens

From September 27-30, members of the Medscape Education Global team were in Athens, Greece sharing 5 posters at the International Myeloma Society Annual Meeting, 2023.The posters presented the outcomes and...

Medscape Education

Top 10 benefits of virtual advisory boards: Save Time and Resources

We've broken down the top ten benefits of why virtual advisory boards are superior to in-person and hybrid advisory boards. #1. Countless Hours of Time-savings and Substantially Reduced Costs We’ll...

Impetus Digital

- PMLiVE

NIHR launches new framework to highlight health progress outcomes

Over 400 partners and stakeholders collaborated to develop the new framework

- PMLiVE

UKHSA secures UK-based vaccine deal for future influenza pandemics

CSL Sequiris will be ready to produce over 100 million influenza pandemic vaccines

- PMLiVE

Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases

The new method analysed over five million people from diverse populations

- PMLiVE

Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments

The companies will work together to develop new cardiovascular treatments

- PMLiVE

Landscape review reveals £1.1bn of UK funding for rare diseases

The report focuses on future funding and needs for those with rare diseases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links